Literature DB >> 22049080

Anion activation site of insulin-degrading enzyme.

Nicholas Noinaj1, Eun Suk Song, Sonia Bhasin, Benjamin J Alper, Walter K Schmidt, Louis B Hersh, David W Rodgers.   

Abstract

Insulin-degrading enzyme (IDE) (insulysin) is a zinc metallopeptidase that metabolizes several bioactive peptides, including insulin and the amyloid β peptide. IDE is an unusual metallopeptidase in that it is allosterically activated by both small peptides and anions, such as ATP. Here, we report that the ATP-binding site is located on a portion of the substrate binding chamber wall arising largely from domain 4 of the four-domain IDE. Two variants having residues in this site mutated, IDEK898A,K899A,S901A and IDER429S, both show greatly decreased activation by the polyphosphate anions ATP and PPPi. IDEK898A,K899A,S901A is also deficient in activation by small peptides, suggesting a possible mechanistic link between the two types of allosteric activation. Sodium chloride at high concentrations can also activate IDE. There are no observable differences in average conformation between the IDE-ATP complex and unliganded IDE, but regions of the active site and C-terminal domain do show increased crystallographic thermal factors in the complex, suggesting an effect on dynamics. Activation by ATP is shown to be independent of the ATP hydrolysis activity reported for the enzyme. We also report that IDEK898A,K899A,S901A has reduced intracellular function relative to unmodified IDE, consistent with a possible role for anion activation of IDE activity in vivo. Together, the data suggest a model in which the binding of anions activates by reducing the electrostatic attraction between the two halves of the enzyme, shifting the partitioning between open and closed conformations of IDE toward the open form.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22049080      PMCID: PMC3249101          DOI: 10.1074/jbc.M111.264614

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Hsp70 molecular chaperone facilitates endoplasmic reticulum-associated protein degradation of cystic fibrosis transmembrane conductance regulator in yeast.

Authors:  Y Zhang; G Nijbroek; M L Sullivan; A A McCracken; S C Watkins; S Michaelis; J L Brodsky
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

3.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

4.  The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates.

Authors:  I Beis; E A Newsholme
Journal:  Biochem J       Date:  1975-10       Impact factor: 3.857

5.  Insulin-degrading enzyme exists inside of rat liver peroxisomes and degrades oxidized proteins.

Authors:  M Morita; I V Kurochkin; K Motojima; S Goto; T Takano; S Okamura; R Sato; S Yokota; T Imanaka
Journal:  Cell Struct Funct       Date:  2000-10       Impact factor: 2.212

6.  ATP inhibits insulin-degrading enzyme activity.

Authors:  M C Camberos; A A Pérez; D P Udrisar; M I Wanderley; J C Cresto
Journal:  Exp Biol Med (Maywood)       Date:  2001-04

7.  Importance of F1-ATPase residue alpha-Arg-376 for catalytic transition state stabilization.

Authors:  S Nadanaciva; J Weber; S Wilke-Mounts; A E Senior
Journal:  Biochemistry       Date:  1999-11-23       Impact factor: 3.162

8.  Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates.

Authors:  E S Song; A Mukherjee; M A Juliano; J S Pyrek; J P Goodman; L Juliano; L B Hersh
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

9.  Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.

Authors:  Bonnie C Miller; Elizabeth A Eckman; Kumar Sambamurti; Nicole Dobbs; K Martin Chow; Christopher B Eckman; Louis B Hersh; Dwain L Thiele
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

10.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.

Authors:  Wesley Farris; Stefan Mansourian; Yang Chang; Loren Lindsley; Elizabeth A Eckman; Matthew P Frosch; Christopher B Eckman; Rudolph E Tanzi; Dennis J Selkoe; Suzanne Guenette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-12       Impact factor: 11.205

View more
  12 in total

Review 1.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Authors:  Wei-Jen Tang
Journal:  Trends Endocrinol Metab       Date:  2015-12-02       Impact factor: 12.015

2.  Inositol phosphates and phosphoinositides activate insulin-degrading enzyme, while phosphoinositides also mediate binding to endosomes.

Authors:  Eun Suk Song; HyeIn Jang; Hou-Fu Guo; Maria A Juliano; Luiz Juliano; Andrew J Morris; Emilia Galperin; David W Rodgers; Louis B Hersh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-21       Impact factor: 11.205

Review 3.  Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.

Authors:  Md Shofiul Azam; Md Wahiduzzaman; Md Reyad-Ul-Ferdous; Md Nahidul Islam; Mukta Roy
Journal:  Pharm Res       Date:  2022-04-04       Impact factor: 4.200

4.  Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme.

Authors:  Lauren A McCord; Wenguang G Liang; Evan Dowdell; Vasilios Kalas; Robert J Hoey; Akiko Koide; Shohei Koide; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-06       Impact factor: 11.205

5.  Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-β hydrolysis.

Authors:  Julie Charton; Marion Gauriot; Qing Guo; Nathalie Hennuyer; Xavier Marechal; Julie Dumont; Malika Hamdane; Virginie Pottiez; Valerie Landry; Olivier Sperandio; Marion Flipo; Luc Buee; Bart Staels; Florence Leroux; Wei-Jen Tang; Benoit Deprez; Rebecca Deprez-Poulain
Journal:  Eur J Med Chem       Date:  2014-04-04       Impact factor: 6.514

Review 6.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

7.  An Extended Polyanion Activation Surface in Insulin Degrading Enzyme.

Authors:  Eun Suk Song; Mehmet Ozbil; Tingting Zhang; Michael Sheetz; David Lee; Danny Tran; Sheng Li; Rajeev Prabhakar; Louis B Hersh; David W Rodgers
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

8.  Proteasome Activity Is Affected by Fluctuations in Insulin-Degrading Enzyme Distribution.

Authors:  Diego Sbardella; Grazia Raffaella Tundo; Francesca Sciandra; Manuela Bozzi; Magda Gioia; Chiara Ciaccio; Umberto Tarantino; Andrea Brancaccio; Massimo Coletta; Stefano Marini
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

9.  Cysteine 904 is required for maximal insulin degrading enzyme activity and polyanion activation.

Authors:  Eun Suk Song; Manana Melikishvili; Michael G Fried; Maria A Juliano; Luiz Juliano; David W Rodgers; Louis B Hersh
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates.

Authors:  Matias B de Tullio; Valeria Castelletto; Ian W Hamley; Pamela V Martino Adami; Laura Morelli; Eduardo M Castaño
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.